|
A review of resent possible targeting therapies on active, moderate to severe thyroid eye disease |
|---|---|
| รหัสดีโอไอ | |
| Creator | Natha Chongpison |
| Title | A review of resent possible targeting therapies on active, moderate to severe thyroid eye disease |
| Publisher | Text and Journal Publication |
| Publication Year | 2561 |
| Journal Title | Vajira Medical Journal |
| Journal Vol. | 62 |
| Journal No. | 3 |
| Keyword | Thyroid eye disease, target therapy |
| URL Website | https://tci-thaijo.org/index.php/VMED |
| Website title | Vajira Medical Journal (วชิรเวชสาร) |
| ISSN | 0125-1252 |
| Abstract | Thyroid eye disease (TED) is an autoimmune inflammatory disorder affected the orbital tissue of which orbital fibroblast is the main target cell. Although the pathogenesis of TED is not fully understood and corticosteroid being a standard treatment of active, moderate to severe TED. An improvement on knowledge in pathogenesis of TED made the ways for others target therapy. The purpose for targeted therapy is to modify a course of TED and not just control the inflammation. The possible targets for future therapy are TSH receptor (TSH-R), IGF-1 receptor (IGF-1R), and platelet-derived growth factor (PDGF) receptor, somatostatin receptor, B cell (CD20), T cell (CD3, CTLA4) and cytokines (tumor necrosis factor-?, interleukin-1, and interleukin-6). |
